High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
about
Radiotherapy and "new" drugs-new side effects?Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and NeckCetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results.Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.Double-blind randomized study of oral glutamine on the management of radio/chemotherapy-induced mucositis and dermatitis in head and neck cancerTreatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocolAdverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerA phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp.Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.Rash rates with egfr inhibitors: meta-analysis.Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multiManagement of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients.Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Current strategies in radiotherapy of head and neck cancer.Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.Cetuximab: its unique place in head and neck cancer treatmentCorrelation of dynamic changes in γ-H2AX expression in peripheral blood lymphocytes from head and neck cancer patients with radiation-induced oral mucositis.Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximabSquamous cell carcinoma of the head and neck in the elderly.Radiation techniques used in patients with breast cancer: Results of a survey in Spain.Current concepts in clinical radiation oncology.Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.Cetuximab in the treatment of squamous cell carcinoma of the head and neck.The emerging era of personalized therapy in squamous cell carcinoma of the head and neck.Molecular targeting agents in the context of primary chemoradiation strategies.Individualization of cancer treatment from radiotherapy perspective.Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment.Lack of a correlation between γH2AX foci kinetics in lymphocytes and the severity of acute normal tissue reactions during IMRT treatment for head and neck cancer.The desire to survive: the adaptation process of adult cancer patients undergoing radiotherapy.Inhibition of the Continuum of Radiation-Induced Normal Tissue Injury by a Redox-Active Mn Porphyrin.Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck.
P2860
Q26861498-5181328A-61AA-4C79-88E2-D31E85854DC5Q28076894-2C2C9332-8833-4E4F-BA31-676C0AEF9C1DQ33410822-BCBEB15F-106D-40D1-97C4-8B8E6DFBE08AQ33426350-849C063A-54D9-4958-8F33-B834C081B65BQ33748313-815ABD85-0EED-49A1-AF24-F88764210705Q33756191-1B433E7B-D6E0-488B-AD70-D87549F70D98Q33983656-4C486BAF-8670-470E-92E6-AF89D3987B93Q34041735-7B3B2D43-4CFA-4C2F-AFE9-92F000A16967Q34084382-430D7302-CAEB-4A32-BEB2-2930FDF7A069Q34343043-1308863C-D8F0-4B14-83B8-1F802BFAE7E4Q34413836-521B59DA-54EF-4D34-AC66-3BB03129688AQ34436771-B8739B01-0B17-45A1-855D-42E16DD993B2Q34618994-B36FEA43-E77E-486A-B6BF-BEF5AAA79235Q34761646-7349A8AF-A473-43D6-919C-9D6A2B389160Q34820775-E9C535B8-868E-4586-844F-0E9CD9672F07Q35584416-9DBE8018-28BF-4750-907E-25C3EB688542Q36078657-EB417EFB-1B27-4A36-AFCC-D3075361C414Q36371601-575AA2F5-8A20-4627-AACA-4906AB7172CDQ36507559-51F8FEB9-B269-4C34-9FC3-599CD94DA802Q36529865-F388F376-CB1E-4FA3-930E-8967EAAB6C3AQ36710452-60B8EB6C-6440-479A-8A06-32A6B33C16D2Q36727111-A291DEB3-CCFE-46D6-A56E-41AC72B304A2Q36880604-78EB5F3C-C7B9-4FF5-9DD1-AA01826753ADQ37000957-B4E31CB4-4F08-4F48-B515-54B4E85473A2Q37146157-7C80D5EF-B436-498B-9ADF-DC06CCEF7E86Q37392126-4C8DF39C-986E-420C-9C53-6BBE4C57F9D4Q37392375-0C1E166C-FEE2-47C7-94D1-A910090427C8Q37603804-70D03F4E-4AFD-4F61-9055-F36B6E2C0B02Q37605840-A10275B8-86C1-423F-83C4-40C902EFF746Q37644848-D709FD8E-1CC0-438D-93E2-EADB38C8B265Q37866779-B0ACBE99-F72D-44A9-B2AB-3D3878CA6186Q37925133-2CB367DF-12CB-42AE-8245-D41BCE2E3179Q37977877-041BFD58-E40B-4B61-A6F1-4C40D8AEF9C3Q37989616-6C38FA18-E337-45A7-94B3-510427B10291Q38382066-2EF5A538-D635-4703-A75B-768D71BBA8BEQ38550172-D04A685A-9900-4A67-81A0-E7E13CA30949Q38563791-B8D3117D-C4C7-4245-B47D-B44965DAA57DQ38703100-C5640624-BA29-44BF-A111-FB78086B68A0Q38851239-508F99E0-618F-4B04-950D-3DC65DF2CA52Q38936131-674DB083-30BF-4D7C-AD32-ED9585C53839
P2860
High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
High rate of severe radiation ...... a survey in EORTC institutes.
@en
High rate of severe radiation ...... a survey in EORTC institutes.
@nl
type
label
High rate of severe radiation ...... a survey in EORTC institutes.
@en
High rate of severe radiation ...... a survey in EORTC institutes.
@nl
prefLabel
High rate of severe radiation ...... a survey in EORTC institutes.
@en
High rate of severe radiation ...... a survey in EORTC institutes.
@nl
P2093
P1476
High rate of severe radiation ...... a survey in EORTC institutes.
@en
P2093
A Gerry Robertson
Bernhard Berger
Christian Giro
Edwin Bölke
Frederic Duprez
I Frank Ciernik
Johannes A Langendijk
Mahmut Ozsahin
Raphael Pfeffer
Sophie Maillard
P304
P356
10.1016/J.RADONC.2008.09.007
P577
2008-10-30T00:00:00Z